Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $15.63 USD
Change Today -0.54 / -3.34%
Volume 16.3K
PRTO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

proteon therapeutics inc (PRTO) Snapshot

Open
$15.69
Previous Close
$16.17
Day High
$15.75
Day Low
$14.75
52 Week High
04/14/15 - $17.26
52 Week Low
12/8/14 - $8.57
Market Cap
257.1M
Average Volume 10 Days
23.2K
EPS TTM
$-3.16
Shares Outstanding
16.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTEON THERAPEUTICS INC (PRTO)

Related News

No related news articles were found.

proteon therapeutics inc (PRTO) Related Businessweek News

No Related Businessweek News Found

proteon therapeutics inc (PRTO) Details

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in a Phase III clinical trials for the treatment of radiocephalic arteriovenous fistula to enable hemodialysis; has completed a Phase I/II clinical trials for the treatment of patients undergoing surgical placement of an arteriovenous graft; and is in a Phase I clinical trials for the treatment of symptomatic peripheral artery diseases. The company was founded in 2001 and is headquartered in Waltham, Massachusetts.

11 Employees
Last Reported Date: 03/20/15
Founded in 2001

proteon therapeutics inc (PRTO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $467.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $440.9K
Vice President of Marketing & Business Develo...
Total Annual Compensation: $242.4K
Compensation as of Fiscal Year 2013.

proteon therapeutics inc (PRTO) Key Developments

Proteon Therapeutics Announces Positive Long-Term Results from Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease

Proteon Therapeutics Inc. announced positive results from a long-term analysis of more than three years of follow-up data from a Phase 2 study of its lead candidate, vonapanitase (formerly PRT-201). The study evaluated the safety and efficacy of vonapanitase, an investigational drug, in patients with chronic kidney disease (CKD) undergoing surgical creation of an arteriovenous fistula (AVF) for hemodialysis. The Phase 2 multicenter, randomized, double-blind, placebo-controlled clinical study evaluated safety and efficacy of a single application of vonapanitase delivered immediately after surgical creation of an AVF. Data from the long-term analysis, to be presented at the National Kidney Foundation's (NKF) 2015 Spring Clinical Meetings in Dallas, demonstrated a trend of prolonged primary patency, the study's primary endpoint, and a statistically significant improvement in the rate of corrective procedures, a secondary endpoint, over more than three years of follow-up for the 30 mcg vonapanitase dose as compared to placebo. An analysis of the results in the subset of patients receiving a radiocephalic AVF, which was not pre-specified, showed statistically significant improvements in primary patency, secondary patency (AVF survival) and the rate of corrective procedures over more than three years of follow-up for the 30 mcg vonapanitase dose as compared to placebo. A radiocephalic AVF is the preferred form of hemodialysis vascular access and is currently being studied in a Phase 3 clinical trial of vonapanitase.

Proteon Therapeutics Inc Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Proteon Therapeutics Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported loss from operations of $7,580 compared to $7,122 reported a year ago. Net loss was $3,342 or $3.16 per basic and diluted share compared to $7,912 or $59.66 per basic and diluted share reported a year ago. Revenue was $2,948. Revenue in 2014 was related to deferred revenue recognized as revenue upon the expiration in August 2014 of residual rights under an option agreement with a major pharmaceutical company originally entered into in 2009.

Proteon Therapeutics Inc Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 09:20 AM

Proteon Therapeutics Inc Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 09:20 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTO:US $15.63 USD -0.54

PRTO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTO.
View Industry Companies
 

Industry Analysis

PRTO

Industry Average

Valuation PRTO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 63.3x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 61.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTEON THERAPEUTICS INC, please visit www.proteontherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.